21177871_1|21177871|18381|#section_info|0:0|In order to identify small molecules disrupting AKAP-PKA interactions, we developed an ELISA-based screening assay, where full-length AKAP18delta was added to RIIalpha subunits of PKA bound to 384-well microtiter plates. Interaction was detected using primary antibodies specific for AKAP18d , secondary peroxidase-conjugated antibodies, and a chemiluminescent peroxidase substrate (Fig. 1A) (12).|#main_body|GO:0034237|protein kinase A regulatory subunit binding|#go_definition|IDA|GOA|Akap7(361458)|#gene_synonym
0.7	21177871_42|21177871|5820|EXPERIMENTAL PROCEDURES|0:0|An ELISA-based assay, established for the detection of the AKAP18delta-RIIalpha interaction (12), was used for screening a small molecule library (FMP_20.000) with 20,064 compounds in 384-well plates.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.7	21177871_136|21177871|19579|RESULTS|0:0|Binding of AKAP18delta to RIIalpha was detected by incubation with primary anti-AKAP18delta (A18delta4 antibody (17)) and secondary peroxidase-coupled antibodies and subsequently with a chemiluminescence peroxidase substrate solution.|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.69	21177871_171|21177871|24887|RESULTS|0:0|RIalpha subunits were captured on 8-AHA-cAMP sensor chip surfaces, and a fragment of the dual specificity AKAP, D-AKAP1 (AKAP149) encompassing the RI/RII interacting domain (amino acids 285-387) (30) was allowed to bind to the RIalpha subunits in the absence or presence of FMP-API-1/27.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.66	21177871_176|21177871|26160|RESULTS|0:0|With the AKAP18delta-derived peptides coupled to the Biacore sensor chips, the SPR experiments (Fig. 1, B and D) were designed in such a way that the small molecules require either interference with the interacting surfaces or allosteric binding to RII subunits to inhibit the interaction.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.66	21177871_177|21177871|26160|RESULTS|0:0|In order to investigate whether the small molecules act through interference with the interacting domains, SPR sensor chips were coated with full-length RIIalpha, and the association and dissociation of FMP-API-1, FMP-API-1/27, and Ht31 or each small molecule combined with the peptide was measured (Fig. 1E).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.65	21177871_57|21177871|7354|EXPERIMENTAL PROCEDURES|0:0|Binding of human PKA regulatory subunit RIIalpha or RIIbeta to the AKAP18delta-L314E peptide surface and inhibition of RII binding by tested compounds were analyzed using a Biacore 3000 instrument (GE Healthcare) as described (17-19).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.65	21177871_179|21177871|26160|RESULTS|0:0|In addition, the additive binding of the PKA disruptor peptide Ht31 along with FMP-API-1 would not be observed if the small molecule interfered with R subunit dimerization because this is required for AKAP binding.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.65	21177871_415|21177871|58229|RESULTS|0:0|To rule out the possibility that FMP-API-1 induces a global increase in the phosphorylation of PKA substrates, cardiac myocytes were incubated with the molecule, and phosphorylated PKA substrates were detected with an antibody directed against the consensus motif, RRX(S/T), phosphorylated by PKA (Fig. 6C).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.64	21177871_59|21177871|7354|EXPERIMENTAL PROCEDURES|0:0|Where indicated, RIalpha, RIbeta, RIIalpha, and RIIbeta were bound to 8-AHA-cAMP-coupled sensor chips as described (19).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.64	21177871_154|21177871|22674|RESULTS|0:0|In the SPR measurements, the peptide AKAP18delta-L314E was immobilized on the chip surface, and recombinant RIIalpha subunits preincubated with FMP-API-1 (50 mum) were added.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	21177871_56|21177871|7354|EXPERIMENTAL PROCEDURES|0:0|Solution competition assays based on surface plasmon resonance (SPR) were performed using streptavidin-coated sensor chips (GE Healthcare) to capture the N-terminally biotinylated peptide AKAP18delta-L314E, derived from the RII-binding domain of AKAP18delta (12).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	21177871_60|21177871|7354|EXPERIMENTAL PROCEDURES|0:0|For direct binding studies, a Biacore S51 instrument (GE Healthcare) was used to monitor compound binding to immobilized RIIalpha.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	21177871_446|21177871|62915|DISCUSSION|0:0|Based on high throughput screening and subsequent chemical modification, we have identified small molecules, namely FMP-API-1 and its derivative FMP-API-1/27, that disrupt interactions between AKAPs and PKA.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.62	21177871_85|21177871|12024|EXPERIMENTAL PROCEDURES|0:0|The non-radioactive PepTag PKA assay (Promega, Madison, WI) was used to measure PKA activity from cell lysates and immunoprecipitates and to measure activity of recombinant catalytic subunits.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.62	21177871_134|21177871|18381|RESULTS|0:0|lt The assay was validated using the PKA anchoring disruptor peptide, AKAP18delta-L314E, derived from the RII-binding domain of AKAP18delta (12).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.62	21177871_142|21177871|19579|RESULTS|0:0|The peptide AKAP18delta-L314E was coupled to sensor chip surfaces, and RIIalpha (500 nm), preincubated with the small molecules (50 mum), was added.|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.62	21177871_234|21177871|33619|RESULTS|0:0|RIIalpha subunits were immunoprecipitated (IP), and co-immunoprecipitated catalytic Calpha subunits of PKA were detected by Western blotting (WB).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.62	21177871_517|21177871|74466|DISCUSSION|0:0|In summary, the identification of the small molecules described here lays the groundwork for the development of high affinity small molecules disrupting the interaction of PKA with AKAPs as well as for revealing novel mechanisms underlying this interaction.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	21177871_76|21177871|10532|EXPERIMENTAL PROCEDURES|0:0|AKAP150, phospho-phospholamban (both from Upstate), cardiac troponin I (c-TnI), c-TnI phosphorylated at Ser23/24, PKA substrates phosphorylated by PKA at the consensus site RRX(S/T) (all from Cell Signaling Technology, Boston, MA), Yotiao (Novus Biologicals Inc., Littleton, CO), calsequestrin (GeneTex, San Antonio, TX), catalytic Calpha, RIIalpha, and RIIbeta subunits of PKA (BD Biosciences), and AKAP18delta (17) were detected by Western blot with specific primary and peroxidase-conjugated secondary antibodies.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	21177871_146|21177871|19579|RESULTS|0:0|The peptide was coupled to SPR sensor chips, and RIIalpha and RIIbeta, preincubated with FMP-API-1/27 (391 nm to 200 mum), were added to determine the IC50 values for the inhibitory effect of the molecule.|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	21177871_188|21177871|28622|RESULTS|0:0|STD NMR experiments showed that the observed inhibition was due to direct binding of FMP-API-1 to the relevant RIIalpha truncates because binding was detected for RIIalpha 1-259 and RIIalpha 1-366, but not for RIIalpha 1-44, RIIalpha 1-72, and RIIalpha 1-87 (data not shown).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	21177871_228|21177871|33619|RESULTS|0:0|A, left, recombinant RIIalpha (0.013 ng) and catalytic subunits (0.0167 mg/ml) of PKA were incubated with DMSO (0.1%), the solvent of FMP-API-1 as a control, and cAMP and/or FMP-API-1 as indicated, and PKA activity was assessed using the PepTag A1 peptide phosphorylation assay as described in the legend to Fig. 2 (mean +- S.E.|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	21177871_282|21177871|39316|RESULTS|0:0|RIIbeta subunits were immunoprecipitated from untreated cells and cells preincubated with FMP-API-1 (100 mum), and co-immunoprecipitated Calpha subunits were detected by Western blotting (Fig. 3B).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	21177871_461|21177871|64861|DISCUSSION|0:0|Our attempts to exactly map the binding region of FMP-API-1 using further truncated versions of RIIalpha were compromised because the required recombinant proteins were insoluble (e.g.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
##EndOfRet##
21177871_2|21177871|18381|#section_info|0:0|This peptide inhibited the AKAP18delta-RIIalpha subunit interaction with an IC50 value of 10 nm, whereas the inactive control peptide AKAP18delta-PP did not affect the interaction in concentrations of up to 1 mm|#main_body|GO:0034237|protein kinase A regulatory subunit binding|#go_definition|IDA|GOA|Akap7(361458)|#gene_synonym
0.68	21177871_146|21177871|19579|RESULTS|0:0|The peptide was coupled to SPR sensor chips, and RIIalpha and RIIbeta, preincubated with FMP-API-1/27 (391 nm to 200 mum), were added to determine the IC50 values for the inhibitory effect of the molecule.|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.68	21177871_159|21177871|23049|RESULTS|0:0|Titrations revealed that FMP-API-1/27 inhibited the interaction of RIIalpha subunits with the peptide AKAP-18delta-L314E with IC50 = 4.0 +- 0.1 mum (Fig. 1C).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.65	21177871_158|21177871|23049|RESULTS|0:0|At a concentration of 50 mum, FMP-API-1/27 and FMP-API-1/28 inhibited the interaction of RII subunits with the peptide by 75 and 70%, respectively (Fig. 1B).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.65	21177871_187|21177871|28622|RESULTS|0:0|Further elongation to amino acid 366 (constructs RIIalpha 1-259 and RIIalpha 1-366) impaired the inhibitory effect of the compound to the peptides on the sensor chips (reduction in binding to 60-70%).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.64	21177871_135|21177871|19579|RESULTS|0:0|, microtiter plates were coated with RIIalpha (15 ng/well) and incubated with AKAP18delta (15 ng/well) in the presence of the PKA anchoring disruptor peptide AKAP18delta-L314E, the inactive control peptide AKAP18delta-PP, or FMP-API-1 in the indicated concentrations (12).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.64	21177871_465|21177871|66024|DISCUSSION|0:0|With respect to inhibition of AKAP-PKA interactions, FMP-API-1 and derivatives resemble PKA anchoring disruptor peptides, such as Ht31 and AKAP18delta-derived peptides, which block AKAP-PKA interactions by binding to the D/D domain of regulatory subunits (6, 10, 12, 50).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.62	21177871_157|21177871|23049|RESULTS|0:0|SPR measurements revealed that only derivatives FMP-API-1/27 and FMP-API-1/28 disrupted the interaction of the peptide AKAP18delta-L314E with RIIalpha subunits effectively.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	21177871_176|21177871|26160|RESULTS|0:0|With the AKAP18delta-derived peptides coupled to the Biacore sensor chips, the SPR experiments (Fig. 1, B and D) were designed in such a way that the small molecules require either interference with the interacting surfaces or allosteric binding to RII subunits to inhibit the interaction.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	21177871_333|21177871|46609|RESULTS|0:0|The cells were preincubated with the PDE4 inhibitor rolipram, the PKA inhibitor H89, the PKA-anchoring disruptor peptide Ht31, the inactive control peptide Ht31P, or FMP-API-1 in the indicated concentrations.|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
##EndOfRet##
21177871_3|21177871|19579|#section_info|0:0|FMP-API-1 inhibits the interaction between AKAP18delta and RIIalpha by allosteric binding to the RII subunits. |#fig_caption|GO:0034237|protein kinase A regulatory subunit binding|#go_definition|IDA|GOA|Prkar2a(29699)|#gene_synonym
0.81	21177871_277|21177871|39316|RESULTS|0:0|RII subunits bind to the catalytic subunits and potently inhibit their activity.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.74	21177871_133|21177871|18275|RESULTS|0:0|FMP-API-1 Inhibits AKAP-PKA Interactions by Allosteric Non-covalent Binding to Regulatory Subunits of PKA|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.71	21177871_176|21177871|26160|RESULTS|0:0|With the AKAP18delta-derived peptides coupled to the Biacore sensor chips, the SPR experiments (Fig. 1, B and D) were designed in such a way that the small molecules require either interference with the interacting surfaces or allosteric binding to RII subunits to inhibit the interaction.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.71	21177871_261|21177871|36576|RESULTS|0:0|In the SPR experiments, the interaction of RII subunits with cAMP occurs under flow, which may impair a transient interaction of RII with cAMP and lead to a significant decrease in RII binding to cAMP.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.7	21177871_167|21177871|24887|RESULTS|0:0|Due to the similarity between RIIalpha and RIIbeta subunits, the interactions between both subunits and AKAPs may be inhibited by the small molecules.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.7	21177871_450|21177871|62915|DISCUSSION|0:0|The fact that the new small molecule disruptors so markedly affect the binding of AKAPs to regulatory subunits without interaction with the core AKAP-regulatory subunit interface and the fact that they act additively with Ht31 peptides (Fig. 1E) point to the binding site as a so far unknown allosteric regulatory site.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.69	21177871_5|21177871|153|abstract|0:0|The molecules bind to an allosteric site of regulatory subunits of PKA identifying a hitherto unrecognized region that controls AKAP-PKA interactions.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.69	21177871_145|21177871|19579|RESULTS|0:0|C, FMP-API-1 inhibits the interactions between regulatory RIIalpha and RIIbeta subunits of PKA with the peptide AKAP18delta-L314E.|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.69	21177871_280|21177871|39316|RESULTS|0:0|The addition of either cAMP (5 mum) or FMP-API-1 (100 mum and 1 mm) induced an increase in the activity of the catalytic subunits in the presence of RII subunits, suggesting that FMP-API-1 binding to regulatory subunits (Fig. 1) dissociates catalytic from regulatory subunits.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.69	21177871_449|21177871|62915|DISCUSSION|0:0|To date, the D/D domain has been the only portion of the RII subunits implicated in either direct binding or regulation of binding to AKAPs (5, 9).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.68	21177871_171|21177871|24887|RESULTS|0:0|RIalpha subunits were captured on 8-AHA-cAMP sensor chip surfaces, and a fragment of the dual specificity AKAP, D-AKAP1 (AKAP149) encompassing the RI/RII interacting domain (amino acids 285-387) (30) was allowed to bind to the RIalpha subunits in the absence or presence of FMP-API-1/27.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.67	21177871_468|21177871|66024|DISCUSSION|0:0|Thus, blocking of the canonical AKAP-interacting site, namely the D/D domain, either directly with peptides or indirectly through the binding of a small molecule to an allosteric site, inhibits AKAP-RII subunit interactions.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.66	21177871_14|21177871|1414|Introduction|0:0|Binding of cAMP to the R subunits induces a conformational change, causing the release and thus activation of the catalytic subunits, which then phosphorylate various substrates (1).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.66	21177871_174|21177871|24887|RESULTS|0:0|Thus, the small molecules inhibit both RI and RII interactions with AKAPs.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.66	21177871_451|21177871|62915|DISCUSSION|0:0|The small molecules interfere with cAMP binding of the regulatory subunits (Figs. 1H and 2B).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.65	21177871_12|21177871|1414|Introduction|0:0|PKA holoenzyme consists of a dimer of regulatory subunits (RIalpha, RIbeta, RIIalpha, or RIIbeta) and two catalytic subunits (Calpha, Cbeta, or Cgamma), each bound to an R subunit.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.65	21177871_57|21177871|7354|EXPERIMENTAL PROCEDURES|0:0|Binding of human PKA regulatory subunit RIIalpha or RIIbeta to the AKAP18delta-L314E peptide surface and inhibition of RII binding by tested compounds were analyzed using a Biacore 3000 instrument (GE Healthcare) as described (17-19).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.65	21177871_454|21177871|62915|DISCUSSION|0:0|This inhibitory site binds to the active site cleft of the catalytic subunit in the holoenzyme.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.64	21177871_26|21177871|3520|Introduction|0:0|Both small molecules interfering with interactions by association with the interacting surfaces or by allosteric binding have been identified (14-16).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.64	21177871_209|21177871|30822|RESULTS|0:0|This prevents binding of regulatory PKA subunits to cAMP-agarose and thereby precipitation of AKAPs.|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.64	21177871_225|21177871|33000|RESULTS|0:0|Targeting a region involving the autoinhibitory domain with small molecules may not only displace RII subunits from AKAPs but may also modulate the activity of PKA.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.64	21177871_274|21177871|39316|RESULTS|0:0|The binding region of FMP-API-1 may involve the autoinhibitory region and/or the nucleotide binding regions of regulatory subunits (Fig. 1, F-H).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.64	21177871_460|21177871|64861|DISCUSSION|0:0|In addition, such studies may require compounds binding with higher affinity to RII subunits than those currently available.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.64	21177871_465|21177871|66024|DISCUSSION|0:0|With respect to inhibition of AKAP-PKA interactions, FMP-API-1 and derivatives resemble PKA anchoring disruptor peptides, such as Ht31 and AKAP18delta-derived peptides, which block AKAP-PKA interactions by binding to the D/D domain of regulatory subunits (6, 10, 12, 50).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	21177871_16|21177871|2164|Introduction|0:0|AKAPs bind PKA through an amphipathic alpha-helical structure consisting of 14-18 amino acids (RII-binding domain), which interacts with the hydrophobic groove formed by the N-terminal dimerization and docking (D/D) domain of regulatory subunit dimers (2-5).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	21177871_179|21177871|26160|RESULTS|0:0|In addition, the additive binding of the PKA disruptor peptide Ht31 along with FMP-API-1 would not be observed if the small molecule interfered with R subunit dimerization because this is required for AKAP binding.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	21177871_257|21177871|36576|RESULTS|0:0|Cyclic AMP-agarose retains regulatory subunits of PKA, including associated binding proteins, such as AKAPs.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	21177871_278|21177871|39316|RESULTS|0:0|cAMP causes the dissociation of C subunits from RII subunits and thereby activation of the catalytic subunits.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	21177871_456|21177871|62915|DISCUSSION|0:0|Taken together, not only does the D/D domain seem to interact with RII-binding domains of AKAPs, but additional regions of the regulatory PKA subunits are involved in the interaction.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.62	21177871_223|21177871|33000|RESULTS|0:0|This region of regulatory subunits is apparently also crucial for the binding of AKAPs.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.62	21177871_447|21177871|62915|DISCUSSION|0:0|The D/D domain at the N terminus of the RII subunits is the interface at which AKAPs interact through their RII-binding domains.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	21177871_458|21177871|64861|DISCUSSION|0:0|In order to fully understand the molecular mechanisms underlying the effects of FMP-API-1 on AKAP-PKA interactions and PKA activity, solved structures of complexes of full-length RII subunits with and without compounds (and of AKAP-R subunit complexes) are needed.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
##EndOfRet##
21177871_4|21177871|19579|#section_info|0:0|FMP-API-1 inhibits the interaction between AKAP18delta and RIIalpha by allosteric binding to the RII subunits. |#fig_caption|GO:0005515|protein binding|#go_definition|IPI|GOA|Prkar2a(29699)|#gene_synonym
0.81	21177871_277|21177871|39316|RESULTS|0:0|RII subunits bind to the catalytic subunits and potently inhibit their activity.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.74	21177871_133|21177871|18275|RESULTS|0:0|FMP-API-1 Inhibits AKAP-PKA Interactions by Allosteric Non-covalent Binding to Regulatory Subunits of PKA|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.71	21177871_176|21177871|26160|RESULTS|0:0|With the AKAP18delta-derived peptides coupled to the Biacore sensor chips, the SPR experiments (Fig. 1, B and D) were designed in such a way that the small molecules require either interference with the interacting surfaces or allosteric binding to RII subunits to inhibit the interaction.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.71	21177871_261|21177871|36576|RESULTS|0:0|In the SPR experiments, the interaction of RII subunits with cAMP occurs under flow, which may impair a transient interaction of RII with cAMP and lead to a significant decrease in RII binding to cAMP.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.7	21177871_167|21177871|24887|RESULTS|0:0|Due to the similarity between RIIalpha and RIIbeta subunits, the interactions between both subunits and AKAPs may be inhibited by the small molecules.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.7	21177871_450|21177871|62915|DISCUSSION|0:0|The fact that the new small molecule disruptors so markedly affect the binding of AKAPs to regulatory subunits without interaction with the core AKAP-regulatory subunit interface and the fact that they act additively with Ht31 peptides (Fig. 1E) point to the binding site as a so far unknown allosteric regulatory site.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.69	21177871_5|21177871|153|abstract|0:0|The molecules bind to an allosteric site of regulatory subunits of PKA identifying a hitherto unrecognized region that controls AKAP-PKA interactions.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.69	21177871_145|21177871|19579|RESULTS|0:0|C, FMP-API-1 inhibits the interactions between regulatory RIIalpha and RIIbeta subunits of PKA with the peptide AKAP18delta-L314E.|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.69	21177871_280|21177871|39316|RESULTS|0:0|The addition of either cAMP (5 mum) or FMP-API-1 (100 mum and 1 mm) induced an increase in the activity of the catalytic subunits in the presence of RII subunits, suggesting that FMP-API-1 binding to regulatory subunits (Fig. 1) dissociates catalytic from regulatory subunits.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.69	21177871_449|21177871|62915|DISCUSSION|0:0|To date, the D/D domain has been the only portion of the RII subunits implicated in either direct binding or regulation of binding to AKAPs (5, 9).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.68	21177871_171|21177871|24887|RESULTS|0:0|RIalpha subunits were captured on 8-AHA-cAMP sensor chip surfaces, and a fragment of the dual specificity AKAP, D-AKAP1 (AKAP149) encompassing the RI/RII interacting domain (amino acids 285-387) (30) was allowed to bind to the RIalpha subunits in the absence or presence of FMP-API-1/27.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.67	21177871_468|21177871|66024|DISCUSSION|0:0|Thus, blocking of the canonical AKAP-interacting site, namely the D/D domain, either directly with peptides or indirectly through the binding of a small molecule to an allosteric site, inhibits AKAP-RII subunit interactions.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.66	21177871_14|21177871|1414|Introduction|0:0|Binding of cAMP to the R subunits induces a conformational change, causing the release and thus activation of the catalytic subunits, which then phosphorylate various substrates (1).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.66	21177871_174|21177871|24887|RESULTS|0:0|Thus, the small molecules inhibit both RI and RII interactions with AKAPs.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.66	21177871_451|21177871|62915|DISCUSSION|0:0|The small molecules interfere with cAMP binding of the regulatory subunits (Figs. 1H and 2B).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.65	21177871_12|21177871|1414|Introduction|0:0|PKA holoenzyme consists of a dimer of regulatory subunits (RIalpha, RIbeta, RIIalpha, or RIIbeta) and two catalytic subunits (Calpha, Cbeta, or Cgamma), each bound to an R subunit.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.65	21177871_57|21177871|7354|EXPERIMENTAL PROCEDURES|0:0|Binding of human PKA regulatory subunit RIIalpha or RIIbeta to the AKAP18delta-L314E peptide surface and inhibition of RII binding by tested compounds were analyzed using a Biacore 3000 instrument (GE Healthcare) as described (17-19).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.65	21177871_454|21177871|62915|DISCUSSION|0:0|This inhibitory site binds to the active site cleft of the catalytic subunit in the holoenzyme.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.64	21177871_26|21177871|3520|Introduction|0:0|Both small molecules interfering with interactions by association with the interacting surfaces or by allosteric binding have been identified (14-16).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.64	21177871_209|21177871|30822|RESULTS|0:0|This prevents binding of regulatory PKA subunits to cAMP-agarose and thereby precipitation of AKAPs.|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.64	21177871_225|21177871|33000|RESULTS|0:0|Targeting a region involving the autoinhibitory domain with small molecules may not only displace RII subunits from AKAPs but may also modulate the activity of PKA.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.64	21177871_274|21177871|39316|RESULTS|0:0|The binding region of FMP-API-1 may involve the autoinhibitory region and/or the nucleotide binding regions of regulatory subunits (Fig. 1, F-H).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.64	21177871_460|21177871|64861|DISCUSSION|0:0|In addition, such studies may require compounds binding with higher affinity to RII subunits than those currently available.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.64	21177871_465|21177871|66024|DISCUSSION|0:0|With respect to inhibition of AKAP-PKA interactions, FMP-API-1 and derivatives resemble PKA anchoring disruptor peptides, such as Ht31 and AKAP18delta-derived peptides, which block AKAP-PKA interactions by binding to the D/D domain of regulatory subunits (6, 10, 12, 50).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	21177871_16|21177871|2164|Introduction|0:0|AKAPs bind PKA through an amphipathic alpha-helical structure consisting of 14-18 amino acids (RII-binding domain), which interacts with the hydrophobic groove formed by the N-terminal dimerization and docking (D/D) domain of regulatory subunit dimers (2-5).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	21177871_179|21177871|26160|RESULTS|0:0|In addition, the additive binding of the PKA disruptor peptide Ht31 along with FMP-API-1 would not be observed if the small molecule interfered with R subunit dimerization because this is required for AKAP binding.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	21177871_257|21177871|36576|RESULTS|0:0|Cyclic AMP-agarose retains regulatory subunits of PKA, including associated binding proteins, such as AKAPs.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	21177871_278|21177871|39316|RESULTS|0:0|cAMP causes the dissociation of C subunits from RII subunits and thereby activation of the catalytic subunits.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	21177871_456|21177871|62915|DISCUSSION|0:0|Taken together, not only does the D/D domain seem to interact with RII-binding domains of AKAPs, but additional regions of the regulatory PKA subunits are involved in the interaction.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.62	21177871_223|21177871|33000|RESULTS|0:0|This region of regulatory subunits is apparently also crucial for the binding of AKAPs.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.62	21177871_447|21177871|62915|DISCUSSION|0:0|The D/D domain at the N terminus of the RII subunits is the interface at which AKAPs interact through their RII-binding domains.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	21177871_458|21177871|64861|DISCUSSION|0:0|In order to fully understand the molecular mechanisms underlying the effects of FMP-API-1 on AKAP-PKA interactions and PKA activity, solved structures of complexes of full-length RII subunits with and without compounds (and of AKAP-R subunit complexes) are needed.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
##EndOfRet##
21177871_5|21177871|19579|#section_info|0:0|E, the peptide Ht31 and the small molecules FMP-API-1 and FMP-API-1/27 bind additively to RIIalpha. |#fig_caption|GO:0036094|small molecule binding|#go_definition|IDA|GOA|Prkar2a(29699)|#gene_synonym
0.61	21177871_450|21177871|62915|DISCUSSION|0:0|The fact that the new small molecule disruptors so markedly affect the binding of AKAPs to regulatory subunits without interaction with the core AKAP-regulatory subunit interface and the fact that they act additively with Ht31 peptides (Fig. 1E) point to the binding site as a so far unknown allosteric regulatory site.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
##EndOfRet##
21177871_6|21177871|19579|#section_info|0:0|F, FMP-API-1 binds to full-length PKA RIIalpha. |#fig_caption|GO:0036094|small molecule binding|#go_definition|IDA|GOA|Prkar2a(29699)|#gene_synonym
0.68	21177871_227|21177871|33619|RESULTS|0:0|FMP-API-1 activates PKA.|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.64	21177871_524|21177871|75651|Supplementary Material|0:0|PKA|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	21177871_6|21177871|153|abstract|0:0|FMP-API-1 also activates PKA.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	21177871_12|21177871|1414|Introduction|0:0|PKA holoenzyme consists of a dimer of regulatory subunits (RIalpha, RIbeta, RIIalpha, or RIIbeta) and two catalytic subunits (Calpha, Cbeta, or Cgamma), each bound to an R subunit.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	21177871_13|21177871|1414|Introduction|0:0|RI-containing holoenzyme is termed PKA type I, whereas RII-containing PKA is termed PKA type II.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	21177871_145|21177871|19579|RESULTS|0:0|C, FMP-API-1 inhibits the interactions between regulatory RIIalpha and RIIbeta subunits of PKA with the peptide AKAP18delta-L314E.|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.62	21177871_16|21177871|2164|Introduction|0:0|AKAPs bind PKA through an amphipathic alpha-helical structure consisting of 14-18 amino acids (RII-binding domain), which interacts with the hydrophobic groove formed by the N-terminal dimerization and docking (D/D) domain of regulatory subunit dimers (2-5).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.62	21177871_57|21177871|7354|EXPERIMENTAL PROCEDURES|0:0|Binding of human PKA regulatory subunit RIIalpha or RIIbeta to the AKAP18delta-L314E peptide surface and inhibition of RII binding by tested compounds were analyzed using a Biacore 3000 instrument (GE Healthcare) as described (17-19).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.62	21177871_86|21177871|12024|EXPERIMENTAL PROCEDURES|0:0|The PepTag PKA assay is based on the phosphorylation of the fluorescent PKA substrate peptide, Leu-Arg-Arg-Ala-Ser-Leu-Gly (Kemptide) (PepTag A1 peptide), which, upon phosphorylation by PKA, acquires a negative charge and can be separated from the non-phosphorylated peptide by agarose gel electrophoresis.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.62	21177871_171|21177871|24887|RESULTS|0:0|RIalpha subunits were captured on 8-AHA-cAMP sensor chip surfaces, and a fragment of the dual specificity AKAP, D-AKAP1 (AKAP149) encompassing the RI/RII interacting domain (amino acids 285-387) (30) was allowed to bind to the RIalpha subunits in the absence or presence of FMP-API-1/27.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.62	21177871_257|21177871|36576|RESULTS|0:0|Cyclic AMP-agarose retains regulatory subunits of PKA, including associated binding proteins, such as AKAPs.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.62	21177871_415|21177871|58229|RESULTS|0:0|To rule out the possibility that FMP-API-1 induces a global increase in the phosphorylation of PKA substrates, cardiac myocytes were incubated with the molecule, and phosphorylated PKA substrates were detected with an antibody directed against the consensus motif, RRX(S/T), phosphorylated by PKA (Fig. 6C).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	21177871_179|21177871|26160|RESULTS|0:0|In addition, the additive binding of the PKA disruptor peptide Ht31 along with FMP-API-1 would not be observed if the small molecule interfered with R subunit dimerization because this is required for AKAP binding.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
##EndOfRet##
21177871_7|21177871|27450|#section_info|0:0|Binding of FMP-API-1 to the full-length RIIalpha subunit is noncovalent and reversible (Fig. 1F).|#main_body|GO:0036094|small molecule binding|#go_definition|IDA|GOA|Prkar2a(29699)|#gene_synonym
##EndOfRet##
21177871_8|21177871|27450|#section_info|0:0|Additional support for non-covalent binding of FMP-API-1 to RIIalpha subunits stems from mass spectrometric analyses of recombinant RIIalpha subunits after incubation with the compound (2 h, room temperature).|#main_body|GO:0036094|small molecule binding|#go_definition|IDA|GOA|Prkar2a(29699)|#gene_synonym
0.67	21177871_280|21177871|39316|RESULTS|0:0|The addition of either cAMP (5 mum) or FMP-API-1 (100 mum and 1 mm) induced an increase in the activity of the catalytic subunits in the presence of RII subunits, suggesting that FMP-API-1 binding to regulatory subunits (Fig. 1) dissociates catalytic from regulatory subunits.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	21177871_450|21177871|62915|DISCUSSION|0:0|The fact that the new small molecule disruptors so markedly affect the binding of AKAPs to regulatory subunits without interaction with the core AKAP-regulatory subunit interface and the fact that they act additively with Ht31 peptides (Fig. 1E) point to the binding site as a so far unknown allosteric regulatory site.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.62	21177871_12|21177871|1414|Introduction|0:0|PKA holoenzyme consists of a dimer of regulatory subunits (RIalpha, RIbeta, RIIalpha, or RIIbeta) and two catalytic subunits (Calpha, Cbeta, or Cgamma), each bound to an R subunit.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.62	21177871_167|21177871|24887|RESULTS|0:0|Due to the similarity between RIIalpha and RIIbeta subunits, the interactions between both subunits and AKAPs may be inhibited by the small molecules.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.62	21177871_171|21177871|24887|RESULTS|0:0|RIalpha subunits were captured on 8-AHA-cAMP sensor chip surfaces, and a fragment of the dual specificity AKAP, D-AKAP1 (AKAP149) encompassing the RI/RII interacting domain (amino acids 285-387) (30) was allowed to bind to the RIalpha subunits in the absence or presence of FMP-API-1/27.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	21177871_14|21177871|1414|Introduction|0:0|Binding of cAMP to the R subunits induces a conformational change, causing the release and thus activation of the catalytic subunits, which then phosphorylate various substrates (1).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	21177871_101|21177871|14207|EXPERIMENTAL PROCEDURES|0:0|To measure the activity of PKA catalytic subunits in vitro, 5 mul of recombinant catalytic subunits (0.0167 mg/ml) were incubated with PepTag A1 peptide (0.056 mug/mul) in PepTag PKA reaction buffer (final volume 25 mul) at 30  C for 10 min with or without 0.013 mg/ml recombinant RII subunits or 0.04 mum cAMP or FMP-API-1 as indicated in the figure legends.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	21177871_183|21177871|28622|RESULTS|0:0|Further confirmation that the binding site of FMP-API-1/27 in RIIalpha subunits is located C-terminal to the D/D domain stems from SPR experiments using the truncations of RIIalpha indicated in Fig. 1G.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	21177871_185|21177871|28622|RESULTS|0:0|The molecule reduced the binding of full-length RIIalpha subunits (amino acids 1-404) to the AKAP18delta-derived peptides coupled to the sensor chips to ~15-20%.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	21177871_277|21177871|39316|RESULTS|0:0|RII subunits bind to the catalytic subunits and potently inhibit their activity.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
##EndOfRet##
21177871_9|21177871|42353|#section_info|0:0|These show that FMP-API-1 (100 mum), applied through the patch pipette, abolished Ca2+ current increases stimulated by the beta-adrenergic agonist ISO (100 nm).|#main_body|GO:0051928|positive regulation of calcium ion transport|#go_definition|IDA|GOA|Adrb1(24925)|#gene_synonym
0.68	21177871_298|21177871|43314|RESULTS|0:0|The cells were left untreated (without) or perfused with FMP-API-1 (100 mum) via the patch pipette as indicated.|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.65	21177871_286|21177871|39316|RESULTS|0:0|Fig. 3C shows that 100 mum FMP-API-1 activated PKA and that 300 mum FMP-API-1 increased PKA activity to a level similar to that reached if the cells had been treated with isoproterenol (100 nm).|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.65	21177871_299|21177871|43314|RESULTS|0:0|Increases in Ca2+ currents were induced by ISO (1 mum) (top) or the channel activator Bay K8644 (Bay; 70 nm) (bottom).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.63	21177871_305|21177871|43314|RESULTS|0:0|Cells were preincubated with compound and dialyzed with cAMP (200 mum) and okadaic acid (OA; 0.2 mum) in the absence or presence of FMP-API-1 (100 mum) via the patch pipette.|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	21177871_198|21177871|30822|RESULTS|0:0|A, rat neonatal cardiac myocytes were treated with FMP-API-1 (300 mum) or ISO (100 nm) either alone or in combination (FMP-API-1 + ISO).|#fig_caption|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	21177871_315|21177871|44608|RESULTS|0:0|For activation of PKA, the cells were perfused through the patch pipette with cAMP together with the protein phosphatase inhibitor, okadaic acid.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
0.61	21177871_351|21177871|49168|RESULTS|0:0|Stimulation with PGE1 (1 mum) induces synthesis of cAMP, which binds to CNGC, opening the channels and facilitating Ca2+ entry.|#main_body|#go_id|#go_term|#go_definition|#evidence_code|#evidence_type|#gene_name|#gene_synonym
##EndOfRet##
